|
| Expression of 14-3-3-zeta in patients with stage Ⅲ/Ⅳ mantle cell lymphoma and its clinical significance |
| Received:May 23, 2016 Revised:August 21, 2016 |
| View Full Text View/Add Comment Download reader |
| DOI：10.11915/j.issn.1671-5403.2016.11.192 |
| Key words:14-3-3zeta protein lymphoma, mantle cell prognosis |
| Author Name | Affiliation | E-mail | | ZHU Mi-Na1, WANG Jian-Hong2, HAO Cai-Xia2, WANG Wen-Yong3, ZHANG Na2, JIA Wei-Jing2, TANG Hai-Long2, DONG Bao-Xia2, GU Hong-Tao2, ZHANG Tao2, YANG Lan2, GAO Guang-Xun2, CHEN Xie-Qun2, WANG Zhe3, LIANG Rong2* | 1Department of Emergency, Xi’an No.1 Hospital, Xi’an 710002, China
2Department of Hematology, 3Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi’an 710032, China | rongliang1017@yahoo.com |
|
| Hits: 1831 |
| Download times: 950 |
| Abstract: |
| Objective To investigate the relationships of 14-3-3zeta protein expression with the therapeutic efficacy and prognosis of the patients with mantle cell lymphoma (MCL). Methods Clinical data of 12 MCL patients who were confirmed pathologically and treated in the Department of Hematology of Xijing Hospital between March 2007 and March 2012 were collected and analyzed. The protein expression of 14-3-3zeta in the patients was detected immunohistochemically, and its correlation with the prognosis of the patients was analyzed. Results Compared with reactive lymphoid hyperplasia, 8 cases showed positive expression of 14-3-3zeta in the cytoplasm, accounting for 66.7%. The overall response rate (ORR), and 2-year overall survival (OS) and 2-year progression-free survival (PFS) were 62.5%,50.0% and 37.5% respectively in the patients with positive expression of 14-3-3zeta, significantly lower than those in the negative expression patients (75.0%, 100.0 and 75.0%). Our results need in-depth study with larger samples. Conclusion MCL patients have abnormally high expression of 14-3-3zeta protein, and its expression level may be correlated with the patients’prognosis. |
| Close |
|
|
|